Humacyte reports preliminary FY2025 revenue $2M, 61 Symvess units; suspends ATM

Humacyte, Inc.

Preliminary FY2025: cash $50.9M, total revenue $2.0M (product $1.4M), 61 Symvess unit sales.
Received $1.48M minimum purchase commitment from KSA entity for Symvess; exclusive negotiations through July 2026.
Filed Marketing Authorization Application in Israel for Symvess in vascular trauma; also pursuing hospital-by-hospital access.
Suspended $60M ATM program effective March 19, 2026; no further sales unless new prospectus filed.
Risk factors updated; accumulated deficit $702M as of Sep 2025, company expects need for additional funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.